Involvement of midkine in autoimmune and autoinflammatory diseases

References

• Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun. 1988;151(3):1312–8.
   PubMed Web of Science ®Google Scholar
• Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999;57(3):253–7.
   PubMed Web of Science ®Google Scholar
• Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99(4):655–62.
   PubMed Web of Science ®Google Scholar
• Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995;86(7):655–61.
   PubMedGoogle Scholar
• Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med. 2000;124(6):848–52.
   PubMed Web of Science ®Google Scholar
• Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem. 1997;122(2):453–8.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2004;50(5):1420–9.
   PubMedGoogle Scholar
• Yamamoto H, Muramatsu H, Nakanishi T, Natori Y, Sakuma S, Ishiguro N, et al. Midkine as a molecular target: comparison of effects of chondroitin sulfate E and siRNA. Biochem Biophys Res Commun. 2006;351(4):915–9.
   PubMed Web of Science ®Google Scholar
• Shindo E, Nanki T, Kusunoki N, Shikano K, Kawazoe M, Sato H, et al. The growth factor midkine may play a pathophysiological role in rheumatoid arthritis. Mod Rheumatol. 2017;27(1):54–9.
   PubMed Web of Science ®Google Scholar
• Wu GC, Yuan H, Pan HF, Ye DQ. Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus. Oncotarget 2017;8(25):40181–9.
   PubMedGoogle Scholar
• Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Circulating midkine in Crohn’s disease: clinical implications. Inflamm Bowel Dis. 2010;16(2):208–15.
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Gorska S, Diakowska D, Kapturkiewicz B, Podkowik M, Gamian A, Bednarz-Misa I. Midkine is up-regulated in both cancerous and inflamed bowel, reflecting lymph node metastasis in colorectal cancer and clinical activity of ulcerative colitis. Cytokine. 2017;89:68–75.
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Clinical relevance of circulating midkine in ulcerative colitis. Clin Chem Lab Med. 2009;47(9):1085–90.
   PubMed Web of Science ®Google Scholar
• Takeuchi H. Midkine and multiple sclerosis. Br J Pharmacol. 2014;171(4):931–5.
   PubMed Web of Science ®Google Scholar
• Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, et al. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999;73:2084–92.
   PubMed Web of Science ®Google Scholar
• Sandra F, Harada H, Nakamura N, Ohishi M. Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol. 2004;40(3):274–80.
   PubMed Web of Science ®Google Scholar
• Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004;204(2):127–43.
   PubMed Web of Science ®Google Scholar
• Mitsiadis TA, Salmivirt M, Muramatsu T, Muramatsu H, Rauvala H, Lehtonen E, et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development. 1995;121(1):37–51.
   PubMed Web of Science ®Google Scholar
• Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, et al. Human ryudocan from endothelial-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem. 1996;271(10):5914–20.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Kadomatsu K, Okamoto T, Ichihara-Tanaka K, Kojima T, SaitoH, et al. Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine. J Biochem. 1997;121:197–205.
   PubMed Web of Science ®Google Scholar
• Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem. 1999;274(18):12474–9.
   PubMed Web of Science ®Google Scholar
• Sakaguchi N, Muramatsu H, Ichihara-Tanak K, Maeda N, Noda M, Yamamoto T, et al. Receptor-type protein tyrosine phosphatase zeta as a component of the signaling receptor complex for midkine-dependent survival of embryonic neurons. Neurosci Res. 2003;45(2):219–24.
   PubMed Web of Science ®Google Scholar
• Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277(39):35990–8.
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T. LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun. 2000;270(3):936–41.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol. 2002;22(19):6788–96.
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Zou P, Suzuki H, Oda Y, Chen GY, Sakaguchi N, et al. alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci. 2004;117(Pt 22):5405–15.
   PubMed Web of Science ®Google Scholar
• Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects. Br J Pharmacol. 2014; 171(4):814–26.
   PubMed Web of Science ®Google Scholar
• Erguven M, Muramatsu T, Bilir A, editors. Midkine: From Embryogenesis to Pathogenesis and Therapy. Dordrecht, the Netherlands: Springer; 2012.
   Google Scholar
• Muramatsu T. Midkine: a promising molecule for drug development to treat diseases of the central nervous system. Curr Pharm Design. 2011;17(5):410–23.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Chen YM, Hung WT, Li JP, Chen DY, Lan JL, Tan TH. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget 2016;7(36):57593–605.
   PubMedGoogle Scholar
• Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(10):769–79.
   PubMed Web of Science ®Google Scholar
• Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227–324.
   PubMed Web of Science ®Google Scholar
• von Mühlen CA, Chan EK, Anglés-Cano E, Mamula MJ, Garcia-De La Torre I, Fritzler MJ. Advances in autoantibodies in SLE. Lupus 1998;7(8):507–14.
   PubMedGoogle Scholar
• Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004;13(5):344–7.
   PubMed Web of Science ®Google Scholar
• Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol. 2009;21(5):489–94.
   PubMed Web of Science ®Google Scholar
• Lorenz G, Lech M, Anders HJ. Toll-like receptor activation in the pathogenesis of lupus nephritis. Clin Immunol. 2017;185:86–94.
   PubMed Web of Science ®Google Scholar
• Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006;18(5):468–75.
   PubMed Web of Science ®Google Scholar
• Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357–66.
   PubMed Web of Science ®Google Scholar
• Mistry P, Kaplan MJ. Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis. Clin Immunol. 2017;185:59–73.
   PubMed Web of Science ®Google Scholar
• Masuda T, Maeda K, Sato W, Kosugi T, Sato Y, Kojima H, et al. Growth factor midkine promotes T-cell activation through nuclear factor of activated T cells signaling and Th1 cell differentiation in lupus nephritis. Am J Pathol. 2017;187(4):740–51.
   PubMed Web of Science ®Google Scholar
• Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol. 2001;167(6):3463–9.
   PubMed Web of Science ®Google Scholar
• Weckbach LT, Muramatsu T, Walzog B. Midkine in inflammation. ScientificWorldJournal. 2011;11:2491–505.
   PubMedGoogle Scholar
• Sonobe Y, Li H, Jin S, Kishida S, Kadomatsu K, Takeuchi H, et al. Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J Immunol. 2012;188(6):2602–11.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol. 2002;15(3):227–31.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.
   PubMed Web of Science ®Google Scholar
• Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, Miyakawa S, et al. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A. 2008;105(10):3915–20.
   PubMed Web of Science ®Google Scholar
• McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590–605.
   PubMed Web of Science ®Google Scholar
• Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell 2010;140(6):859–70.
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, et al; European Crohn’s and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2(1):24–62.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–31.
   PubMed Web of Science ®Google Scholar